DDInter1230 DDInter1376
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mirtazapine {u} (Compound) resembles {v} (Compound) Mianserin
Mirtazapine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Mirtazapine {u} (Compound) binds {v} (Gene) HTR2C
Mirtazapine {u} (Compound) upregulates {v} (Gene) AGR2
Mirtazapine {u} (Compound) downregulates {v} (Gene) KIF20A
Mirtazapine {u} (Compound) causes {v} (Side Effect) Cardiomegaly
Mirtazapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mirtazapine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Mirtazapine (Compound) resembles Mianserin (Compound)
Mirtazapine (Compound) resembles Chlorcyclizine (Compound)
Mirtazapine (Compound) binds HTR2C (Gene)
Mirtazapine (Compound) upregulates AGR2 (Gene)
Mirtazapine (Compound) downregulates KIF20A (Gene)
Mirtazapine (Compound) causes Cardiomegaly (Side Effect)
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Mirtazapine may lead to a major life threatening interaction when taken with Bupropion